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Abstract
Background: Obesity and related metabolic abnormalities, including inflammation and lipid accumulation in the
liver, play a role in liver carcinogenesis. Adipocytokine imbalances, such as decreased serum adiponectin levels, are
also involved in obesity-related liver tumorigenesis. In the present study, we examined the effects of pitavastatin -
a drug used for the treatment of hyperlipidemia - on the development of diethylnitrosamine (DEN)-induced liver
preneoplastic lesions in C57BL/KsJ-db/db (db/db) obese mice.
Methods: Male db/db mice were administered tap water containing 40 ppm DEN for 2 weeks and were
subsequently fed a diet containing 1 ppm or 10 ppm pitavastatin for 14 weeks.
Results: At sacrifice, feeding with 10 ppm pitavastatin significantly inhibited the development of hepatic
premalignant lesions, foci of cellular alteration, as compared to that in the untreated group by inducing apoptosis,
but inhibiting cell proliferation. Pitavastatin improved liver steatosis and activated the AMPK-a protein in the liver.
It also decreased free fatty acid and aminotransferases levels, while increasing adiponectin levels in the serum. The
serum levels of tumor necrosis factor (TNF)-a and the expression of TNF-a and interleukin-6 mRNAs in the liver
were decreased by pitavastatin treatment, suggesting attenuation of the chronic inflammation induced by excess
fat deposition.
Conclusions: Pitavastatin is effective in inhibiting the early phase of obesity-related liver tumorigenesis and,
therefore, may be useful in the chemoprevention of liver cancer in obese individuals.
Background
Hepatocellular carcinoma (HCC) is a serious healthcare
problem worldwide because of its increasing morbidity
and high mortality. Chronic inflammation of the liver
and subsequent cirrhosis, which are highly correlated
with hepatitis B and hepatitis C viruses infection and
alcoholic liver disease, are the strongest risk factors for
HCC development. Recent evidence also indicates that
obesity and related metabolic abnormalities, especially
diabetes mellitus and insulin resistance, raise the risk of
HCC [1-4]. In obese individuals, high levels of free fatty
acid (FFA) flux into the liver from excess adipose tissue.
This in turn promotes hepatic steatosis and inflamma-
tion through the production of pro-inflammatory cyto-
kines, such as tumor necrosis factor (TNF)-a and
interleukin (IL)-6, and is closely associated with liver
carcinogenesis [5-7]. Aberrant lipogenesis in the liver,
which is closely linked to obesity and metabolic syn-
drome, is also a dominant event in liver carcinogenesis
and human HCC progression [8]. Non-alcoholic fatty
liver disease (NAFLD) is a hepatic manifestation of the
metabolic syndrome and a proportion of patients with
this disease can progress to non-alcoholic steatohepatitis
(NASH), which involves the risk of developing cirrhosis
and HCC [9]. Therefore, in addition to lifestyle modifi-
cation to reduce body weight, active pharmacotherapy is
considered to be necessary for the management of
NASH. For instance, metformin and thiazolidinediones,
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ful for the treatment of patients with NASH [10].
Statins, 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors, are widely used for the
treatment of hyperlipidemia and have been shown to
reduce the risk of cardiovascular disease [11]. Statins
have recently also been suggested to be possible candi-
dates for the management of NASH/NAFLD, which fre-
quently coexist with hyperlipidemia and cardiovascular
disease [12]. A pilot study revealed that treatment with
atorvastatin decreases TNF-a serum levels and improves
biochemical and histological features of disease activity in
NASH patients with dyslipidemia [13]. The use of ator-
vastatin in hyperlipidemic patients complicated with
NAFLD also improves serum transaminase levels and
prevents hepatic fibrosis progression [14]. In a mice
model, pitavastatin, a recently developed lipophilic statin,
has been shown to ameliorate severe hepatic steatosis by
enhancing hepatic free acid (FA) b-oxidation activity [15].
In addition to the lipid-lowering and anti-inflammatory
effects, recent studies have revealed that statins appear to
have anticancer and cancer chemopreventive properties
[16,17]. A large cohort study showed that statin use is
associated with a reduced risk of HCC in patients with
diabetes [18]. Statins inhibit cell proliferation and induce
apoptosis in human HCC-derived cells [19,20]. In addi-
tion, pitavastatin prevents obesity-related colorectal carci-
nogenesis by correcting adipocytokine imbalance and
attenuating colonic inflammation in C57BL/KsJ-db/db
(db/db) mice suffering from obesity and hyperlipidemia
[21]. These findings suggest the possibility that long-term
use of statins may also be effective for preventing the pro-
gression of obesity-related liver tumorigenesis. Our recent
study showed that diethylnitrosamine (DEN)-induced liver
tumorigenesis is significantly enhanced in db/db mice
[22]. In the present study, we examined the effects of pita-
vastatin on the development of DEN-induced hepatic pre-
neoplastic lesions, foci of cellular alteration (FCA), while
focusing on the improvement of liver steatosis and inflam-
mation using a db/db mice model.
Methods
Animals and chemicals
Four-week-old male db/db mice were obtained from
Japan SLC Inc. (Shizuoka, Japan) and were humanely
maintained at the Gifu University Life Science Research
Center in accordance with the Institutional Animal Care
Guidelines. DEN was purchased from Sigma Chemical
Co. (St. Louis, MO, USA). Pitavastatin was obtained
from Kowa Pharmaceutical Co. (Tokyo, Japan).
Experimental procedure
The animal experiment was approved by the Committee of
Institutional Animal Experiments of Gifu University [22].
At 5 weeks of age, all 36 mice were administered tap water
containing 40 ppm DEN for the first 2 weeks of the experi-
ment. After DEN treatment, Groups 2 (n = 12) and 3 (n =
12) were given a basal diet (CRF-1, Oriental Yeast Co.,
Tokyo, Japan) containing 1 and 10 ppm pitavastatin, respec-
tively, until the end of the experiment. Group 1 (n = 12)
acted as the control and was fed only a basal diet through-
out the experiment. At 21 weeks of age (after 14 weeks of
pitavastatin treatment), all the mice were sacrificed to ana-
lyze the development of FCA. Since neither C57B6 nor
C57BL/KsJ-+/+ mice - the genetic controls for db/db mice
- develop FCA and liver neoplasms by DEN administration
during this period [22], control experimentation using these
mice was not conducted in the present study.
Histopathology and immunohistochemical analysis for
PCNA
Maximum sagittal sections of each lobe (6 sublobes)
were used for histopathological examination. For all
experimental groups, 4 μm-thick sections of formalin-
fixed and paraffin-embedded livers were stained with
hematoxylin & eosin (H&E) for histopathology. The pre-
sence of FCA, which are phenotypically altered hepato-
cytes showing swollen and basophilic cytoplasm and
hyperchromatic nuclei, was judged according to the cri-
teria described in a previous study [23]. The multiplicity
of FCA was assessed on a per unit area (cm
2) basis.
Immunohistochemical staining of proliferating cell
nuclear antigen (PCNA), a G1-to-S phase marker, was
performed to estimate the cell proliferative activity of
F C Ab yu s i n ga na n t i - P C N Aa n t i b o d y( S a n t aC r u zB i o -
technology, Santa Cruz, CA, USA) and the labeled strep-
tavidin-biotin method (LSAB kit; DAKO, Glostrup,
Denmark) [22]. On the PCNA-immunostained sections,
the cells with intensively reacted nuclei were considered
to be positive for PCNA, and the indices (%) were calcu-
lated in 20 FCA randomly selected from each group.
Protein extraction and western blot analysis
Equivalent amounts of extracted mice liver proteins (20
μg/lane) were examined by western blot analysis [22].
Previously described primary antibodies for AMP-acti-
vated kinase-a (AMPK-a), phosphorylated AMPK-a (p-
AMPK-a), and glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) were used [21], with GAPDH serving as a
loading control. The primary antibody for Bad was pur-
chased from Cell Signaling Technology (Beverly, MA,
USA). The intensities of the blots were quantified with
NIH Image software version 1.62.
RNA extraction and quantitative real-time reverse
transcription-PCR
Total RNA was isolated from the livers of experimental
mice using the RNAqueous-4PCR kit (Ambion Applied
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from 0.2 μg of total RNA using the SuperScript III
First-Strand Synthesis System (Invitrogen, Carlsbad, CA,
USA). Quantitative real-time reverse transcription-PCR
(RT-PCR) analysis was performed using specific primers
that amplify TNF-a, IL-6, Bcl-2, Bad,a n dGAPDH
genes, as described previously [21,24].
Clinical chemistry
The blood samples, which were collected at the time of
sacrifice after 6 hours of fasting, were used for chemical
analyses. The serum TNF-a (Shibayagi, Gunma, Japan),
IL-6 (IBL, Gunma, Japan), adiponectin (Otsuka, Tokyo,
Japan), and leptin (R&D Systems, Minneapolis, MN,
USA) levels were determined by enzyme immunoassay
according to the manufacturers’ protocol. The serum
levels of aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), free fatty acid (FFA), total choles-
terol, and triglyceride were measured with a standard
clinical automatic analyzer (type 7180; Hitachi, Tokyo,
Japan).
Hepatic lipid analysis
Approximately 200 mg of frozen liver was homogenized,
and lipids were extracted using Folch’sm e t h o d[ 2 5 ] .
The triglyceride levels in the liver were measured using
the triglyceride E-test kit (Wako Pure Chemical Co.,
Osaka, Japan) [22]. To visualize the intrahepatic lipids,
Oil red O staining was utilized based on the standard
procedure for frozen liver sections.
Statistical analysis
The results are presented as means ± SD, and were ana-
lyzed using the GraphPad Instat software program ver-
sion 3.05 (GraphPad Software; San Diego, CA) for
Macintosh. Differences among the groups were analyzed
by either one-way ANOVA or, as required, by two-way
ANOVA. When the ANOVA revealed a statistically sig-
nificant effect (P < 0.05), each experimental group was
compared with the control group by using the Bonferroni
multiple comparisons test. The differences were consid-
ered significant when the two-sided P value was < 0.05.
Results
General observations
As presented in Table 1, administration of pitavastatin
significantly (P < 0.01, Group 1 vs. Groups 2 and 3) and
dose dependently (P < 0.05, Group 2 vs. Group 3)
decreased the value of body mass index (BMI). The
body weight and relative weights of liver and white adi-
pose tissue (periorchis and retroperitoneum) of the mice
that received 10 ppm pitavastatin were slightly lower
than those of the untreated control mice, but the differ-
ences were not significant. During the experiment, pita-
vastatin administration did not cause any clinical
symptoms for toxicity. Histopathological examination
also revealed the absence of pitavastatin toxicity in the
liver, kidney, and spleen (data not shown).
Effects of pitavastatin on DEN-induced liver preneoplastic
lesions in db/db mice
Liver preneoplastic lesion FCA, which possesses baso-
philic cytoplasm and hyperchromatic nuclei (Figure 1A),
was observed in the livers of mice from all groups at the
termination of the experiment. Treatment with a high
dose (10 ppm) of pitavastatin significantly inhibited the
development of FCA in comparison to both the
untreated control mice (P < 0.001) and low dose (1
ppm) of pitavastatin-treated mice (P < 0.05). Treatment
with 1 ppm pitavastatin also demonstrated a tendency
to suppress the development of FCA - the inhibition
rate being 29% - in comparison to the untreated control
mice, but the difference did not reach a statistical signif-
icance (Figure 1B).
Effects of pitavastatin on the cellular levels of Bad and Bcl-
2 and the proliferation activity in FCA of DEN-treated db/
db mice
We next examined the effects of pitavastatin on the
induction of apoptosis in the liver and the inhibition of
cell proliferation in FCA of DEN-treated db/db mice.
Treatment with both low and high doses of pitavastatin
increased the protein levels of Bad, a pro-apoptotic Bcl-
2 family member, in the liver of experimental mice (Fig-
ure 2A, P < 0.05). The mRNA levels of this molecule
Table 1 Body, liver, kidney and white adipose tissue weights of the experimental mice
Group no. Treatment No. of mice Body wt (g) BMI
a Relative wt (g/100 g body wt) of:
Liver Kidney Fat
b
1 DEN alone 12 63.1 ± 7.0
c 7.2 ± 0.6 6.4 ± 1.5 0.9 ± 0.1 9.3 ± 1.0
2 DEN + 1 ppm Pitavastatin 12 59.7 ± 3.9 6.7 ± 0.4
d 6.0 ± 0.8 0.9 ± 0.1 9.1 ± 0.8
3 DEN + 10 ppm Pitavastatin 12 55.2 ± 9.5 6.2 ± 0.6
d,e 5.7 ± 1.2 1.0 ± 0.2 8.7 ± 1.0
aBody mass index.
bWhite adipose tissue of the periorchis and retroperitoneum.
cMean ± SD.
dSignificantly different from Group 1 (P < 0.01).
eSignificantly different from Group 2 (P < 0.05).
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(Figure 2B, P < 0.05). On the other hand, pitavastatin
treatment induced a marked decrease in the levels of an
anti-apoptotic molecule Bcl-2 mRNA (Figure 2B, P <
0.05). In addition, as shown in Figure 2C, the mean
PCNA-labeling indices for FCA in mice treated with 1
ppm (23.9 ± 7.7%) and 10 ppm (16.6 ± 4.0%) pitavasta-
tin were significantly lower than that in the mice which
received only DEN (47.7 ± 11.0%; P < 0.001 for each
comparison). These findings indicate that pitavastatin
significantly suppresses FCA, at least in part, by indu-
cing apoptosis and by reducing cell proliferation.
Effects of pitavastatin on hepatic steatosis, activation of
AMPK-a protein in the liver, and serum levels of FFA, total
cholesterol, and triglyceride in DEN-treated db/db mice
Accumulation of lipids in the liver, which is caused by
dyslipidemia, is considered to play a role in liver tumori-
genesis [5,6]. Therefore, we examined whether pitavasta-
tin improved hepatic steatosis and hyperlipidemia in the
experimental mice. Examination of Oil red O stained
sections revealed severe hepatic steatosis in the DEN-
treated db/db mice; however, the mice’s conditions were
markedly improved by pitavastatin administration (Fig-
ure 3A, upper panels). Similar to the histological find-
ings, the levels of intrahepatic triglyceride were also
significantly reduced by administration of pitavastatin
(Figure 3A, lower panel, P < 0.001). Western blot analy-
sis demonstrated that pitavastatin significantly phos-
phorylated (i.e., activated) AMPK-a - a critical kinase
that monitors cellular energy status [26] - in the livers
of the experimental mice (Figure 3B, P <0 . 0 5 ) .I na d d i -
tion, treatment with both low (P <0 . 0 1 )a n dh i g h( P <
0.001) doses of pitavastatin decreased the serum levels
of FFA, while the levels of total cholesterol and trigly-
ceride were not affected by administration of this agent
(Figure 3C).
Effects of pitavastatin on serum levels of AST, ALT,
adiponectin, and leptin in DEN-treated db/db mice
The serum levels of AST, ALT, adiponectin, and leptin
in the experimental mice are listed in Table 2. The ele-
vated serum AST and ALT levels, which might increase
due to severe steatosis (Figure 3A), were significantly
decreased by treatment with both low (P < 0.001) and
high (P < 0.05) doses of pitavastatin. The serum leptin
levels after pitavastatin administration demonstrated a
downward trend, but the differences were not signifi-
cant. However, treatment with this agent markedly
increased the serum levels of adiponectin when com-
pared to the control mice (P < 0.05).
Effects of pitavastatin on serum TNF-a levels and hepatic
expression of TNF-a and IL-6 mRNAs in DEN-treated db/db
mice
Chronic inflammation induced by excessive production
of storage lipids is closely associated with obesity-related
liver carcinogenesis [5-7]. Therefore, the effects of pita-
vastatin on the serum levels of TNF-a, a central media-
tor of chronic inflammatory disease, and on the
expression of TNF-a and IL-6 mRNAs in the liver of
DEN-treated db/db mice were examined. Administration
Figure 1 Effects of pitavastatin on DEN-induced FCA in db/db mice.( A) A representative photograph of FCA induced by DEN in db/db mice
(H&E staining). Scale bar, 100 μm. (B) Average number of FCA in all groups (pitavastatin-untreated, 1 ppm pitavastatin-treated, and 10 ppm
pitavastatin-treated groups). Each column represents the mean ± SD. * P < 0.05 vs. 1 ppm pitavastatin-treated group and ** P < 0.001 vs. the
untreated group, respectively.
Shimizu et al. BMC Cancer 2011, 11:281
http://www.biomedcentral.com/1471-2407/11/281
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serum TNF-a levels (Figure 4A, P <0 . 0 5 ) .F u r t h e r ,
quantitative real-time RT-PCR revealed that the expres-
sion levels of TNF-a and IL-6 mRNAs in the livers of
experimental mice were also significantly decreased after
pitavastatin treatment (Figure 4B, P < 0.05, respectively),
suggesting that pitavastatin attenuated liver inflamma-
tion in obese db/db mice.
Discussion and Conclusions
Statins lessen hyperlipidemia by competitively inhibiting
HMG-CoA reductase, and thus, they are effective in
preventing cardiovascular disease [11]. On the other
hand, many studies have shown the anticancer and can-
cer chemopreventive effects of statins, such as the inhi-
bition of cell proliferation, promotion of apoptosis, and
inhibition of inflammation, angiogenesis, and metastasis
[16,17,19,20]. The anticancer effects of statins also
involve the inhibition of geranylgeranylation, primary of
the Rho proteins [16,17]. These findings suggest the
possibility of statins playing a role of cancer chemopre-
ventive agents for certain malignancies.
The results of the present study clearly indicated that
pitavastatin, which is widely used for the treatment of
patients with hyperlipedemia, effectively prevents the
development of DEN-induced liver preneoplastic lesions
in obese db/db mice (Figure 1B). This is the first report
that shows the preventive effect of statin analog on the
development of obesity-related liver tumorigenesis. The
unfavorable effects of obesity and related metabolic
abnormalities are serious global healthcare problem.
Among them, the promotion of HCC by obesity [1-4] is
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Figure 2 Effects of pitavastatin on the expression levels of Bad and Bcl-2 in the liver and cell proliferation in FCA induced by DEN in
db/db mice.( A) The total proteins were extracted from the livers of experimental mice and the expression levels of the Bad protein were
examined by western blot analysis (upper panel). The intensities of the blots were quantified by densitometry (lower panel). GAPDH antibody
served as a loading control. Two lanes represent protein samples obtained from 2 different mice in each group. Repeat western blots yielded
similar results. Values are the means ± SD. * P < 0.05 vs. the untreated group. (B) The total RNAs were isolated from the livers of experimental
mice and the expression levels of Bcl-2 and Bad mRNAs were examined by quantitative real-time RT-PCR using specific primers. The expression
levels of each mRNA were normalized to the level of GAPDH mRNA. Values represent the means ± SD. * P < 0.05 vs. the untreated group. (C)
Representative pictures of the PCNA-immunohistochemical analysis of FCA (circled) developed in the livers of Groups 1, 2, and 3 (left panels).
The PCNA-labeling indices of FCA developed in the livers of Groups 1 through 3 were determined by counting the PCNA-positive nuclei in FCA
(right panel). Scale bars, 200 μm (no treatment) and 100 μm (1 and 10 ppm pitavastatin). * P < 0.001 vs. the untreated group.
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Page 5 of 10one of the critical issues that need to be addressed in
the management of this malignancy. Therefore, our pre-
sent finding seems to be clinically significant when con-
sidering the prevention of HCC in obese people, who
are at an increased risk of developing HCC.
The suppressive effect of pitavastatin on the develop-
ment of obesity-related liver tumorigenesis was most
likely associated with the induction of apoptosis in the
liver (Figures. 2A and 2B) and the inhibition of prolif-
eration in FCA (Figure 2C). This inhibition was also
associated with the improvement of hepatic steatosis
(Figure 3A) and the attenuation of inflammation (Figure
4) because excess accumulation of lipids in the liver
accelerates hepatic tumorigenesis by inducing a chronic
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Figure 3 Effects of pitavastatin on hepatic steatosis, activation of the AMPK-a protein in the liver, and serum levels of FFA, total
cholesterol, and triglyceride in DEN-treated db/db mice.( A) Frozen liver sections from experimental mice with or without pitavastatin
treatment were stained with Oil red O to show steatosis (upper panels). Hepatic lipids were extracted from the frozen livers of these mice, and
the triglyceride levels were measured (lower panel). Values are the means ± SD. * P < 0.001 vs. the untreated group. (B) The total proteins were
extracted from the livers of experimental mice and the expression levels of the AMPK-a and p-AMPK-a proteins were examined by western blot
analysis (upper panel). The intensities of the blots were quantified by densitometry (lower panel). GAPDH antibody served as a loading control.
Two lanes represent protein samples obtained from 2 different mice in each group. Repeat western blots yielded similar results. Values are the
means ± SD. * P < 0.05 vs. the untreated group. (C) The serum concentrations of FFA, total cholesterol, and triglyceride in all groups. Values are
the means ± SD. * P < 0.01 and ** P < 0.001 vs. the untreated group, respectively.
Table 2 Serum levels of AST, ALT, adiponectin, and leptin in the experimental mice
Group no. Treatment No. of mice AST
a ALT
b Adiponectin Kidney
(IU/L) (IU/L) (μg/mL) (ng/dL)
1 DEN alone 12 194 ± 47
c 291 ± 112 15.5 ± 2.4 108.1 ± 33.4
2 DEN + 1 ppm Pitavastatin 12 111 ± 28
d 180 ± 49
d 19.2 ± 4.5
e 104.3 ± 33.2
3 DEN + 10 ppm Pitavastatin 12 144 ± 28
e 227 ± 96
e 21.2 ± 7.4
e 93.2 ± 31.2
aaspartate aminotransferase.
balanine aminotransferase.
cMean ± SD.
dSignificantly different from Group 1 (P < 0.001).
eSignificantly different from Group 1 (P < 0.05).
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Page 6 of 10inflammatory reaction [5-7]. Pitavastatin mainly ame-
liorates hepatic steatosis by decreasing serum FFA
levels (Figure 3C) since the high influx of FFA into the
liver plays a major role in hepatic fat accumulation
[5,6]. In addition, activation of AMPK-a by pitavastatin
in the liver (Figure 3B), which increases FA oxidation,
decreases FA synthesis, and improves hyperlipidemia
[26], also contributes to the inhibition of lipid deposi-
tion in the liver. Further, these findings are significant
when considering the prevention of obesity-related car-
cinogenesis because AMPK is regarded as a metabolic
tumor suppressor and a promising target for cancer
prevention and therapy [27]. AMPK activity is asso-
ciated with the inhibition of lipogenesis, which has a
pathogenic and prognostic significance for HCC [8],
induction of apoptosis, and suppression of cell growth
in human HCC-derived cells [28]. Pitavastatin has also
been shown to inhibit obesity-related colorectal
carcinogenesis through the activation of AMPK-a in
the colonic mucosa [21].
In the present study, lipid-lowering effects of pitavas-
tatin were positive on serum FFA but not significant on
total cholesterol and triglyceride in DEN-treated db/db
mice (Figure 3C). These findings are consistent with the
results of a recent study indicating more high doses of
pitavastatin (20 and 40 ppm) did not significantly
decrease the serum levels of total cholesterol and trigly-
ceride in Min mice, which show a hyperlipidemic state
[ 2 9 ] .O nt h ec o n t r a r y ,E g a w aet al.[ 1 5 ]d e m o n s t r a t e d
that pitavastatin administration resulted in a significant
reduction in the levels of plasma triglyceride and total
cholesterol in aromatase-deficient mice. Treatment with
both 1 and 10 ppm pitavastatin for 8 weeks also reduced
serum levels of total cholesterol, but not triglyceride, in
azoxymethane-treated db/db mice [21]. These reports
[15,21,29], together with the results of the present study,
D
D
Figure 4 Effects of pitavastatin on the serum levels of TNF-a and the expression levels of TNF-a and IL-6 mRNAs in the liver of DEN-
treated db/db mice.( A) The serum concentration of TNF-a was measured by enzyme immunoassay. Values represent the means ± SD. * P <
0.05 vs. the untreated group. (B) The total RNAs were isolated from the livers of experimental mice and the expression levels of TNF-a and IL-6
mRNAs were examined by quantitative real-time RT-PCR using specific primers. The expression levels of each mRNA were normalized to the level
of GAPDH mRNA. Values represent the means ± SD. * P < 0.05 vs. the untreated group.
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might depend on the animal strain and experimental
procedure. In addition, it has been shown that pitavasta-
tin potently inhibits de novo cholesterol synthesis with-
out affecting serum lipid levels [30,31]. In rodents,
cholesterol synthesis enzymes were remarkably induced
by feedback regulation [32], suggesting that the effects
of pitavastatin on reduction of plasma lipid and inhibi-
tion of HMG-CoA reductase activity might be masked
by such feedback regulation.
Increases in TNF-a and IL-6 levels, which are accom-
panied by lipid accumulation in the liver, are involved in
obesity-related liver carcinogenesis [5-7]. Therefore,
reduction of serum TNF-a levels (Figure 4A) and inhibi-
tion of the expression of TNF-a and IL-6 mRNAs in the
liver (Figure 4B) by pitavastatin are important in pre-
venting obesity-related liver tumorigenesis. These find-
ings are consistent with previous reports that
pitavastatin significantly suppresses inflammation- and
obesity-related mouse colon carcinogenesis by attenuat-
ing chronic inflammation [21,33]. The effects of pitavas-
tatin on decreasing the levels of TNF-a might be largely
dependent on the reduction of BMI (Table 1) and
serum FFA levels (Figure 3C). These phenomena may
also be associated with the improvement of adipocyto-
k i n ei m b a l a n c e( T a b l e2 )b e c a u s eT N F - a has been
shown to decrease the levels of adiponectin, which is
secreted by the adipose tissue, while increasing the levels
of leptin in the adipocytes [34,35]. Moreover, up-regula-
tion of serum adiponectin levels (Table 2) also plays a
role in attenuating inflammation because this adipocyto-
kine possesses the ability to down-regulate the produc-
tion of TNF-a and IL-6 [36]. Adiponectin alleviates
hepatic steatosis and ALT abnormalities in alcohol-
induced fatty liver mice model and in ob/ob mice, a
NAFLD mice model, by enhancing FA oxidation, while
decreasing FA synthesis and TNF-a production in the
liver [37]. Hypoadiponectinemia enhances the progres-
sion of steatosis and hepatic tumor formation in a mice
model of NASH [38]. In addition, adiponectin inhibits
cell proliferation and induces apoptosis in human HCC-
derived cells by inducing AMPK activation [39]. There-
fore, the elevation of adiponectin and activation of
AMPK might be effective for the prevention of obesity-
related tumorigenesis.
Hepatotoxicity is one of the critical concerns in treat-
ment with statins. In the present study, however, pita-
vastatin did not cause significant toxicity in the liver as
determined by histological examination. The serum ami-
notransferase (ALT and AST) levels were also decreased
by treatment with this agent (Table 2). The safety of sta-
tins for patients with liver dysfunction has also been
reported in several clinical trials [40]. In addition,
patients with chronic liver disease, including NAFLD/
NASH and HCV infection, may benefit from statins
because cardiovascular risk is likely to be high in these
diseases [12,41]. Therefore, statin use might be a pro-
mising therapy for NASH patients who have an
increased risk of HCC [9], although periodic monitoring
of serum aminotransferase levels should be conducted.
The result of a recent epidemiological study revealing a
significant relationship between the risk reduction of
HCC and statin use among diabetic patients [18] may
also encourage statin therapy for patients with chronic
liver disease, especially NASH patients, who frequently
have hyperlipidemia as well as insulin resistance.
Finally, it should be noted that the results of recent stu-
dies indicating that supplementation with branched-chain
amino acids and acyclic retinoid, both of which exert che-
mopreventive effects on the development of HCC in clini-
cal trials [3,42], suppresses DEN-induced liver
tumorigenesis in db/db mice by improving hepatic steato-
sis and attenuating chronic inflammation [22,43]. In sum-
mary, the results of the present study, together with those
of the cited reports [22,43], suggest that the prevention of
liver carcinogenesis by targeting hepatic steatosis, chronic
inflammation, and adipocytokine imbalance, through
either pharmaceutical or nutritional intervention, might be
a promising strategy for obese individuals who are at an
increased risk of developing HCC. Pitavastatin appears to
be a potentially effective candidate for this purpose since it
can improve liver steatosis and attenuate inflammation, at
least in part, through the activation of AMPK-a and up-
regulation of adiponectin.
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